Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 8/20 | 0.54 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | DRD1 | P21728 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD5 | P21918 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2794352 | 0.80 | TRPM8 (0.44) | DRD2 | |
| SCHEMBL27571779 | 0.80 | PRCP (0.62) | PRCPDRD2HTR1AHTR7DRD1 | |
| SCHEMBL12312001 | 0.76 | PRCP (0.57) | PRCPDRD2HTR1AHTR7DRD1 | |
| SCHEMBL5244031 | 0.76 | DRD2 (0.46) | PRCPDRD2HTR1AHTR7LMNA | |
| SCHEMBL7585522 | 0.75 | PRCP (0.60) | PRCPDRD2HTR1AHTR7DRD1 | |
| SCHEMBL12337795 | 0.75 | CHRM3 (0.41) | DRD2 | |
| SCHEMBL25604565 | 0.72 | PRCP (1.00) | PRCPDRD2DRD1 | |
| SCHEMBL8415128 | 0.72 | PRCP (1.00) | PRCPDRD2DRD1 | |
| SCHEMBL13928812 | 0.72 | PRCP (1.00) | PRCPDRD2DRD1 | |
| Iodide SCHEMBL27518895 | 0.71 | PRCP (0.97) | PRCPDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | PRCP 3639/4885DRD2 202/4885HTR1A 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.